Dr. Laurent Biertho, MD
Claim this profileInstitut Universitaire de Cardiologie et de Pneumologie de Québec
Studies Obesity
Studies Diabetes Mellitus
4 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Laurent Biertho, MD is currently running
Metabolic Surgery
for Obesity
Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question. Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies. With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.
Recruiting1 award N/A2 criteria
Single vs Standard Duodenal Switch
for Obesity
Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However, its technical difficulty and increased risk of long-term nutritional deficiencies have been a major hindrance to its diffusion. Recently, a " simplified " technique of Duodenal-Switch has been proposed by Sanchez-Pernaute et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first duodenum, and connection of the duodenum to an omega-loop of small bowel instead of a terminal intestinal loop used in standard BPD-DS. The overall objective of this study is to assess in a prospective randomized blinded trial, the outcomes of this new procedure, using a comprehensive clinical evaluation and follow-up method. This could potentially change the clinical practice and surgical approach in our Institution.
Recruiting1 award N/A2 criteria
More about Laurent Biertho, MD
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Laurent Biertho, MD has experience with
- Single-anastomosis Duodenal Switch
- Standard Duodenal Switch
- Single Anastomosis Duodenal Switch
- Standard Duodenal Switch
- Duodenal-Ileal Diversion With A Sleeve Gastrectomy
- Biliopancreatic Diversion With Duodenal Switch
Breakdown of trials Laurent Biertho, MD has run
Obesity
Diabetes Mellitus
Diabetes
Bariatric Surgery Candidates
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Laurent Biertho, MD specialize in?
Laurent Biertho, MD focuses on Obesity and Diabetes Mellitus. In particular, much of their work with Obesity has involved treating patients, or patients who are undergoing treatment.
Is Laurent Biertho, MD currently recruiting for clinical trials?
Yes, Laurent Biertho, MD is currently recruiting for 3 clinical trials in Quebec City Quebec. If you're interested in participating, you should apply.
Are there any treatments that Laurent Biertho, MD has studied deeply?
Yes, Laurent Biertho, MD has studied treatments such as Single-anastomosis duodenal switch, Standard duodenal switch, Single Anastomosis Duodenal Switch.
What is the best way to schedule an appointment with Laurent Biertho, MD?
Apply for one of the trials that Laurent Biertho, MD is conducting.
What is the office address of Laurent Biertho, MD?
The office of Laurent Biertho, MD is located at: Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec G1V 4G5 Canada. This is the address for their practice at the Institut Universitaire de Cardiologie et de Pneumologie de Québec.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.